Project description
Point-of-care testing kit for the early sepsis prognosis
Sepsis causes a systemic inflammatory response driven by proinflammatory cytokines and is the leading cause of death in hospital critical care units. Early disease biomarkers are necessary to assist in the decision-making identification of immunocompromised patients. The development of a point-of-care testing kit to enable quick and reliable detection of immunocompromised patients by using blood biomarkers would improve the early prognosis of sepsis. Recently, an in vitro prognostic product was developed that enables the fast detection of early impairment of the NLRP3 inflammasome activation, as a prognostic biomarker in sepsis. The objective of the current EU-funded SPEDI-TEST project is to demonstrate the technical and commercial feasibility, and evaluate the new business opportunity of the clinical introduction of this novel test.
Objective
Sepsis remains the leading cause of death in critical care units of Hospitals, affecting more that 18 million people worldwide and causes a systemic inflammatory response driven by the production of proinflammatory cytokines. Several studies have been conducted to find out whether data mining and machine learning could be used to identify patients at risk of sepsis. Although the currently available biomarkers can help shorten this decision process, there is still a need for additional early disease biomarkers that could anticipate the decision-making identifying immunocompromised septic patients. In this sense, ongoing efforts in the development of a point-of-care testing kit, enabling quick and reliable detection of immunocompromised patients by using blood biomarkers, will aid greatly the early prognosis of sepsis. In this scenario, the prognosis and therapy selection still remains a clinical decision by assessing the patient’s history, symptoms of infection, and development of acute organ dysfunction. Our group have determined under the ERC consolidator grant ref. 614578 (DangerATP) that during the initial 24 h of the inflammatory response in sepsis, monocytes from human septic patients present an early impairment of the activation of the NLRP3 inflammasome that is associated with higher late mortality. This group of septic patients was not identified with any of the clinical or biochemical determinations performed.
We have developed an in vitro prognostic (IVD) product for the fast detection in less than 4 hours of early impairment of the NLRP3 inflammasome activation, as a biomarker for the prognosis in sepsis. This IVD will be used in intensive care units and immunology units of hospitals. The objective of the action is to demonstrate the technical and commercial feasibility and evaluate the new business opportunity of introducing this novel IVD product.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- social sciences sociology demography mortality
- medical and health sciences clinical medicine critical care medicine
- natural sciences computer and information sciences data science data mining
- medical and health sciences basic medicine immunology
- natural sciences computer and information sciences artificial intelligence machine learning
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-POC - Proof of Concept Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2019-PoC
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
30120 MURCIA
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.